New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 23, 2014
05:25 EDTNVSNovartis announces new data confirms efficacy of Gilenya
New analyses of pooled data from the FREEDOMS and FREEDOMS II trials will be presented at the 66th American Academy of Neurology, or AAN, Annual Meeting in Philadelphia, Pennsylvania, and will show the consistent efficacy of Gilenya on four key measures of multiple sclerosis disease activity - reducing relapses, new MRI lesion counts, brain volume loss and disability progression. Demonstrating benefit on these four measures is important in order to improve the course of MS and ultimately address the loss of function experienced by patients with MS. An additional analysis of FREEDOMS and FREEDOMS II will show that significantly more Gilenya-treated patients had brain volume loss rates comparable to people without MS. Given that brain volume loss, measured by MRI, starts early in the disease course and is correlated with long-term disability, a treatment benefit on this measure will be important for patients with MS.
News For NVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 1, 2015
05:16 EDTNVSNovartis division Alcon receives CE Mark for AcryS of IQ Aspheric IOL
Subscribe for More Information
June 30, 2015
05:32 EDTNVSNovartis launches first Apple Watch app for visually impaired people
Novartis Pharmaceuticals (NVS) announced the release of new features for its ViaOpta applications, and the extension for use with smart watches. The discreet, hands-free nature of using ViaOpta app with wearable devices, such as Apple Watch (AAPL) and Android Wear (GOOG), provides users with an experience that seamlessly fits into their existing routines allowing those with visual impairments to navigate daily life with even greater ease.
June 29, 2015
08:35 EDTNVSAnacor announces amendment to KERYDIN commercialization agreement
Subscribe for More Information
05:15 EDTNVSNovartis acquires Spinifex Pharmaceuticals, terms not disclosed
Novartis announced that it has entered into an agreement to acquire Spinifex Pharmaceuticals. Spinifex Pharmaceuticals is a U.S. and Australian-based, privately held development stage company, focused on developing a peripheral approach to treat neuropathic pain such as EMA401, a novel angiotensin II Type 2 receptor, or AT2R, antagonist. Financial terms were not disclosed.
June 26, 2015
07:44 EDTNVSNovartis drug Farydak recommended by CHMP for EU approval
Subscribe for More Information
June 25, 2015
14:02 EDTNVSNovartis initiated with a Buy at HSBC
Price target CHF 115.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use